Wednesday, January 26, 2022
HomeHealthCovid and Johnson & Johnson JNJ earnings Q3 2021

Covid and Johnson & Johnson JNJ earnings Q3 2021

Johnson & Johnson said it sold $502 million of its Covid-19 vaccine in the third quarter, in its earnings report Tuesday that beat Wall Street’s profit expectations.Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:Adjusted EPS: $2.60 per share vs $2.35 expected.Revenue: $23.34 billion vs $23.72 billion expected.Shares of J&J jumped more than 1% in premarket trading. J&J’s report came under a shadow of criticism about how it handled the opioid crisis and the development of a comparatively less-effective Covid vaccine under outgoing CEO Alex Gorsky.In a press release, Gorsky said the financial results “demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health.”This is a developing story. Please check back for updates. Correction: This story was updated to reflect that J&J missed revenue estimates.

image 100365595 14413751



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Most Popular

Recent Comments